AC 0002 - ACEA Therapeutics
Alternative Names: AC0002Latest Information Update: 07 Jun 2021
At a glance
- Originator ACEA Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical CNS cancer
Most Recent Events
- 01 Jun 2021 ACEA Therapeutics has been acquired by Sorrento Therapeutics
- 12 Apr 2021 AC 0002 is available for licensing as of 12 Apr 2021. https://www.aceatherapeutics.com/contact/
- 09 Apr 2021 Preclinical trials in CNS cancer in USA (unspecified route) (ACEA Therapeutics pipeline, April 2021)